| Literature DB >> 29883402 |
Amy G W Gong1,2,3, Ran Duan4,5, Huai Y Wang6,7, Xiang P Kong8,9, Tina T X Dong10,11, Karl W K Tsim12,13, Kelvin Chan14,15,16,17.
Abstract
Astragali Radix (AR), a Chinese materia medica (CMM) known as Huangqi, is an important medicine prescribed in herbal composite formulae (Fufang) by Traditional Chinese medicine (TCM) practitioners for thousands of years. According to the literature, AR is suggested for patients suffering from “Qi”- and “Blood”-deficiencies, and its clinical effects are reported to be related to anti-cancer cell proliferation, anti-oxidation, relief of complications in cardiovascular diseases, etc. The underlying cell signaling pathways involved in the regulation of these various diseases are presented here to support the mechanisms of action of AR. There are two botanical sources recorded in China Pharmacopoeia (CP, 2015): Astragalus membranaceus (Fisch.) Bge. Var. mongohlicus, (Bge.) Hsiao, and Astragalus membranaceus (Fisch.) Bge. (Fam. Leguminosae), whose extracts of dried roots are processed via homogenization-assisted negative pressure cavitation extraction. Geographic factors and extraction methods have impacts on the pharmaceutical and chemical profiles of AR. Therefore, the levels of the major bioactive constituents of AR, including polysaccharides, saponins, and flavonoids, may not be consistent in different batches of extract, and the pharmaceutical efficacy of these bioactive ingredients may vary depending on the source. Therefore, the present review mainly focuses on the consistency of the available sources of AR and extracts and on the investigation of the biological functions and mechanisms of action of AR and of its major bioactive constituents. Furthermore, it will also include a discussion of the most popular AR composite formulae to further elucidate their chemical and biological profiles and understand the pharmaceutical value of AR.Entities:
Keywords: Astragali Radix; pharmaceutical values; traditional Chinese medicine
Year: 2018 PMID: 29883402 PMCID: PMC6023478 DOI: 10.3390/medicines5020046
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Figure 1Sources of Astragali Radix (AR) and plant morphology. (A) AR produce source is widely present in the mainland of China. Astragalus membranaceus is mainly produced in the northwest and west of China (black dots). A. membranaceus var. mongholicus is greatly produced in the west of China, (yellow triangles). AR collected from Shanxi, China, highlighted in red, is believed to be “Di Dao” material. (B) Authentic plants of A. membranaceus (left) and A. membranaceus var. mongholicus (right).
The anti-oxidative functions of AR and its major constituents.
| Working Parts | Biological Functions | Model | References |
|---|---|---|---|
|
| Against oxidation of linoleic acid | In vitro | [ |
| Enhancing anti-oxidant enzymes activities and accumulating osmotic agents | In vitro | [ | |
| Improving DNA repair abilities | In vitro | [ | |
| Upregulating lipideroxidation levels | In vivo | [ | |
|
| Enhancing free radical scavenging activities | In vitro | [ |
| Stimulating lipid peroxidation inhibition levels | In vitro | [ | |
| Decreasing SOD and GSH-Px contents | In vivo | [ | |
|
| Declining high-mobility group box 1 protein content | In vivo | [ |
| Preventing renal and mitochondrial oxidative-induced dysfunctions, possibly through the TLR4/NF-κB pathway | In vivo; | [ | |
|
| Decline of SOD and GSH-Px levels | In vivo | [ |
| Decrease of SOD, GSH-Px, and catalase activities | In vitro | [ |
SOD: Super oxidase dimutase; GSH-Px: Selenium dependent glutathione-peroxidase.
The immunomodulatory functions of AR and its major constituents.
| Working Parts | Biological Functions | Model | References |
|---|---|---|---|
|
| Decrease colonic lesion area and histological damage | In vivo | [ |
| Enhance non-specific immune response | In vivo | [ | |
| Increase of monocytes, neutrophils, and lymphocytes counts | In vivo | [ | |
| Increase Bax/Bcl-2 ratio | In vitro | [ | |
| Suppress proliferation of various cancer cell types | In vitro | [ | |
| Enhance breast cancer patients’ life span and increase their life quality | In vivo | [ | |
|
| T cell and B cell proliferation | In vivo | [ |
| Cytokine upregulation | In vitro | [ | |
| Regulation of GM-CSF and NO productions and modulation of Akt pathway | In vitro | [ | |
| Prolong cancer patient’s lifespan | In vivo | [ | |
| Stimulate tumor cell apoptosis | In vitro | [ | |
| Enhance IgM antibody production | In vivo | [ | |
| Suppress chronic inflammation cytokine level | In vitro | [ | |
| Increase synovial cell apoptosis rate | In vivo | [ | |
|
| Suppress NO and chronic inflammatory mediator release | In vitro | [ |
| Inhibit LPS-stimulated cytokine production in bone marrow-derived dendritic cells | In vitro | [ | |
| Accelerate cancer apoptosis rate | In vitro | [ | |
| Prolong cancer patient’s lifespan | In vivo | [ | |
| Stimulate lymphocyte proliferation | In vitro | [ |
GM-CSF: Granulocyte-macrophage colony stimulating factors.
Other functions of AR and its major constituents.
| Parts | Biological Functions | Model | References |
|---|---|---|---|
|
| Anti-obesity | In vitro; | [ |
|
| Reduction of tumor size | In vivo | [ |
| Downregulation of mTOR expression and interference with DNA binding activity | In vitro | [ | |
| Suppression of VEGF and bFGF levels and downregulation of p-Akt, p-mTaOR, VEGF, VEGFR1, and VEGFR2 | In vitro; | [ | |
| Enhancement of immune response | In vitro; | [ | |
| Induction of BMP-2 and Smad1/5/8 expressions | In vitro | [ |